KIT and amyotrophic lateral sclerosis: Pharmacological and gene therapy approaches targeting Schwann cells and their associated signaling pathways (e.g., c-Kit, CSF-1R, and iNOS) are attractive and viable options for developing novel ALS therapies, thus potentially addressing peripheral nerve inflammation and pathology more effectively.